Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial

We investigated curcumin's efficacy in inducing remission in patients with active mild-to-moderate ulcerative colitis

Alon Lang; Nir Salomon; Justin C.Y. Wu; Uri Kopylov; Adi Lahat; Ofir Har-Noy; Jessica Y.L. Ching; Pui Kuan Cheong; Benjamin Avidan; Dorit Gamus; Ioannis Kaimakliotis; Rami Eliakim; Siew C. Ng; Shomron Ben-Horin

2015

Scholarcy highlights

  • Background & AimsThe phytochemical compound curcumin was reported to be effective in maintaining remission in patients with ulcerative colitis
  • We investigated curcumin's efficacy in inducing remission in patients with active mild-to-moderate UC
  • Addition of curcumin to mesalamine therapy was superior to the combination of placebo and mesalamine in inducing clinical and endoscopic remission in patients with mild-to-moderate active UC, producing no apparent adverse effects
  • 47 failed to meet inclusion criteria: Thirty-one were excluded because of ineligible Simple Clinical Colitis Activity Index score, 5 patients were excluded after sigmoidoscopy revealed a normal colonic mucosa, 4 patients tested positive for C difficile, and 7 patients achieved clinical remission after mesalamine optimization run-in period
  • Endoscopic remission was observed in 8 of 22 patients in the curcumin arm and in 0 of 16 patients receiving placebo, 20.7; 95% confidence intervals
  • Our results showed a marked superiority of curcumin over placebo, we did not perform formal power calculation because there were no previous data testing the efficacy of this drug in this particular setting
  • At the end of a 1-month study, a remarkable 53.8% of patients receiving curcumin achieved a clinical remission compared with none in the control group with parallel endoscopic improvement

Need more features? Save interactive summary cards to your Scholarcy Library.